These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
703 related articles for article (PubMed ID: 20587614)
1. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614 [TBL] [Abstract][Full Text] [Related]
2. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment. Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460 [TBL] [Abstract][Full Text] [Related]
3. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266 [TBL] [Abstract][Full Text] [Related]
4. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348 [TBL] [Abstract][Full Text] [Related]
5. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Farag SS; Archer KJ; Mrózek K; Vardiman JW; Carroll AJ; Pettenati MJ; Moore JO; Kolitz JE; Mayer RJ; Stone RM; Larson RA; Bloomfield CD Int J Oncol; 2002 Nov; 21(5):1041-51. PubMed ID: 12370753 [TBL] [Abstract][Full Text] [Related]
6. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424 [TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of de novo acute myeloid leukemia in Thai patients. Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172 [TBL] [Abstract][Full Text] [Related]
9. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
10. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027 [TBL] [Abstract][Full Text] [Related]
11. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230 [TBL] [Abstract][Full Text] [Related]
13. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Byrd JC; Lawrence D; Arthur DC; Pettenati MJ; Tantravahi R; Qumsiyeh M; Stamberg J; Davey FR; Schiffer CA; Bloomfield CD Clin Cancer Res; 1998 May; 4(5):1235-41. PubMed ID: 9607582 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K; Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435 [TBL] [Abstract][Full Text] [Related]
15. Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome. Jaff N; Chelghoum Y; Elhamri M; Tigaud I; Michallet M; Thomas X Leuk Res; 2007 Jan; 31(1):67-73. PubMed ID: 16814381 [TBL] [Abstract][Full Text] [Related]
16. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ; N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926 [TBL] [Abstract][Full Text] [Related]
17. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Larson RA Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252 [TBL] [Abstract][Full Text] [Related]
18. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663 [TBL] [Abstract][Full Text] [Related]
19. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E; Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930 [TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]